177 related articles for article (PubMed ID: 35196635)
21. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of tumor spread through air spaces for T2aN0 stage IB non-small cell lung cancer.
Chen Z; Wu X; Fang T; Ge Z; Liu J; Wu Q; Zhou L; Shen J; Zhou C
Cancer Med; 2023 Jul; 12(14):15246-15255. PubMed ID: 37278137
[TBL] [Abstract][Full Text] [Related]
23. Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study.
Tamiya A; Koh Y; Isa SI; Kubo A; Ando M; Saka H; Yoshimoto N; Takeo S; Adachi H; Tagawa T; Kawashima O; Yamashita M; Kataoka K; Takenoyama M; Takeuchi Y; Watanabe K; Matsumura A; Kawaguchi T
Cancer Med; 2020 Apr; 9(7):2343-2351. PubMed ID: 32022477
[TBL] [Abstract][Full Text] [Related]
24. Minor (≤ 10%) Ground-Glass Opacity Component in Clinical Stage I Non-Small Cell Lung Cancer: Associations With Pathologic Characteristics and Clinical Outcomes.
Li M; Wang J; Bao X; Wang F; Zhou F; Song N; Wan Z; Li W; Zhang L
AJR Am J Roentgenol; 2024 May; ():. PubMed ID: 38809121
[No Abstract] [Full Text] [Related]
25. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
26. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy.
Li Q; Kim J; Balagurunathan Y; Qi J; Liu Y; Latifi K; Moros EG; Schabath MB; Ye Z; Gillies RJ; Dilling TJ
Radiat Oncol; 2017 Sep; 12(1):158. PubMed ID: 28946909
[TBL] [Abstract][Full Text] [Related]
27. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma.
Yang F; Sun K; Li F; Li X; Shi J; Sun X; Hong Y; Jiang G; Zhu Y; Song X
Ann Thorac Surg; 2024 Jun; 117(6):1111-1119. PubMed ID: 37353101
[TBL] [Abstract][Full Text] [Related]
29. Preoperative Geriatric Nutritional Risk Index: A predictive and prognostic factor in patients with pathological stage I non-small cell lung cancer.
Shoji F; Matsubara T; Kozuma Y; Haratake N; Akamine T; Takamori S; Katsura M; Toyokawa G; Okamoto T; Maehara Y
Surg Oncol; 2017 Dec; 26(4):483-488. PubMed ID: 29113668
[TBL] [Abstract][Full Text] [Related]
30. A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer.
Deng J; Zhao M; Wang T; She Y; Wu J; E H; Gao J; Sun X; Jiang G; Zhu Y; Xie D; Chen C
Lung Cancer; 2020 Jul; 145():33-39. PubMed ID: 32402920
[TBL] [Abstract][Full Text] [Related]
31. [Using Immunohistochemical Markers and Clinicopathological Factors to Predict the Prognostic Survival of Different Types of Endometrial Cancer Recurrence].
Huang Z; Jiang P; Jia MZ; Li L; Deng Y; Lai L; Hu ZY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 May; 52(3):489-496. PubMed ID: 34018370
[TBL] [Abstract][Full Text] [Related]
32. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
[TBL] [Abstract][Full Text] [Related]
33. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
34. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer.
Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH
Clin Lung Cancer; 2016 Sep; 17(5):e31-e43. PubMed ID: 26992846
[TBL] [Abstract][Full Text] [Related]
37. Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study.
Aragaki M; Kato T; Fujiwara-Kuroda A; Hida Y; Kaga K; Wakasa S
J Cardiothorac Surg; 2020 Aug; 15(1):229. PubMed ID: 32859238
[TBL] [Abstract][Full Text] [Related]
38. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.
Ahrendt SA; Hu Y; Buta M; McDermott MP; Benoit N; Yang SC; Wu L; Sidransky D
J Natl Cancer Inst; 2003 Jul; 95(13):961-70. PubMed ID: 12837832
[TBL] [Abstract][Full Text] [Related]
39. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.
Glubb DM; Paré-Brunet L; Jantus-Lewintre E; Jiang C; Crona D; Etheridge AS; Mirza O; Zhang W; Seiser EL; Rzyman W; Jassem J; Auman T; Hirsch FR; Owzar K; Camps C; Dziadziuszko R; Innocenti F
J Thorac Oncol; 2015 Jul; 10(7):1067-75. PubMed ID: 26134224
[TBL] [Abstract][Full Text] [Related]
40. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
